http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Mon, 09 Mar 2026 16:18:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/SEC+Filings/Form++144++++++++HALOZYME+THERAPEUTICS%2C+++++++++++++++++Filed+by%3A+Caudill+Cortney/26132355.html si-local-file:///var/storage/secattach/20260309/26132355.html http://www.streetinsider.com/SEC+Filings/Form++144++++++++HALOZYME+THERAPEUTICS%2C+++++++++++++++++Filed+by%3A+Caudill+Cortney/26132355.html Mon, 09 Mar 2026 16:18:00 -0400 HALO O.00978404 http://www.streetinsider.com/SEC+Filings/Form++144++++++++HALOZYME+THERAPEUTICS%2C+++++++++++++++++Filed+by%3A+Caudill+Cortney/26132355.html si-local-file:///var/storage/secattach/20260309/26132355.html http://www.streetinsider.com/SEC+Filings/Form++144++++++++HALOZYME+THERAPEUTICS%2C+++++++++++++++++Filed+by%3A+Caudill+Cortney/26132355.html Mon, 09 Mar 2026 16:18:00 -0400 HALO O.00978404 http://www.streetinsider.com/FDA/FDA+approves+TECVAYLI+and+DARZALEX+FASPRO+combination+for+multiple+myeloma/26122361.html <p>The U.S. Food and Drug Administration approved TECVAYLI (teclistamab-cqyv) in combination with DARZALEX FASPRO (daratumumab and hyaluronidase-fihj) for treating adults with relapsed or refractory multiple myeloma who have received at least one prior line of therapy.</p> <p>Johnson & Johnson received the approval based on data from the Phase 3 MajesTEC-3 study. The combination treatment demonstrated an 83% reduction in the risk of disease progression or death compared to standard regimens, with a hazard ratio of 0.17. After a median follow-up of three years, the three-year progression-free survival rate was 83%.</p> <p>Both drugs in the approved combination are administered subcutaneously. DARZALEX FASPRO incorporates http://www.streetinsider.com/FDA/FDA+approves+TECVAYLI+and+DARZALEX+FASPRO+combination+for+multiple+myeloma/26122361.html Fri, 06 Mar 2026 08:01:13 -0400 A.06822034 A.19846794 A.27499954 A.30035300 A.50114084 A.50201316 A.50209015 HALO O.00225875 O.00401804 O.00520840 O.00978404 O.01668149 O.07332344 O.20026344 O.20947283 http://www.streetinsider.com/FDA/FDA+approves+TECVAYLI+and+DARZALEX+FASPRO+combination+for+multiple+myeloma/26122361.html <p>The U.S. Food and Drug Administration approved TECVAYLI (teclistamab-cqyv) in combination with DARZALEX FASPRO (daratumumab and hyaluronidase-fihj) for treating adults with relapsed or refractory multiple myeloma who have received at least one prior line of therapy.</p> <p>Johnson & Johnson received the approval based on data from the Phase 3 MajesTEC-3 study. The combination treatment demonstrated an 83% reduction in the risk of disease progression or death compared to standard regimens, with a hazard ratio of 0.17. After a median follow-up of three years, the three-year progression-free survival rate was 83%.</p> <p>Both drugs in the approved combination are administered subcutaneously. DARZALEX FASPRO incorporates http://www.streetinsider.com/FDA/FDA+approves+TECVAYLI+and+DARZALEX+FASPRO+combination+for+multiple+myeloma/26122361.html Fri, 06 Mar 2026 08:01:13 -0400 A.06822034 A.19846794 A.27499954 A.30035300 A.50114084 A.50201316 A.50209015 HALO O.00225875 O.00401804 O.00520840 O.00978404 O.01668149 O.07332344 O.20026344 O.20947283 http://www.streetinsider.com/FDA/FDA+approves+TECVAYLI+and+DARZALEX+FASPRO+combination+for+multiple+myeloma/26122361.html <p>The U.S. Food and Drug Administration approved TECVAYLI (teclistamab-cqyv) in combination with DARZALEX FASPRO (daratumumab and hyaluronidase-fihj) for treating adults with relapsed or refractory multiple myeloma who have received at least one prior line of therapy.</p> <p>Johnson & Johnson received the approval based on data from the Phase 3 MajesTEC-3 study. The combination treatment demonstrated an 83% reduction in the risk of disease progression or death compared to standard regimens, with a hazard ratio of 0.17. After a median follow-up of three years, the three-year progression-free survival rate was 83%.</p> <p>Both drugs in the approved combination are administered subcutaneously. DARZALEX FASPRO incorporates http://www.streetinsider.com/FDA/FDA+approves+TECVAYLI+and+DARZALEX+FASPRO+combination+for+multiple+myeloma/26122361.html Fri, 06 Mar 2026 08:01:13 -0400 A.06822034 A.19846794 A.27499954 A.30035300 A.50114084 A.50201316 A.50209015 HALO O.00225875 O.00401804 O.00520840 O.00978404 O.01668149 O.07332344 O.20026344 O.20947283 http://www.streetinsider.com/FDA/FDA+approves+TECVAYLI+and+DARZALEX+FASPRO+combination+for+multiple+myeloma/26122361.html <p>The U.S. Food and Drug Administration approved TECVAYLI (teclistamab-cqyv) in combination with DARZALEX FASPRO (daratumumab and hyaluronidase-fihj) for treating adults with relapsed or refractory multiple myeloma who have received at least one prior line of therapy.</p> <p>Johnson & Johnson received the approval based on data from the Phase 3 MajesTEC-3 study. The combination treatment demonstrated an 83% reduction in the risk of disease progression or death compared to standard regimens, with a hazard ratio of 0.17. After a median follow-up of three years, the three-year progression-free survival rate was 83%.</p> <p>Both drugs in the approved combination are administered subcutaneously. DARZALEX FASPRO incorporates http://www.streetinsider.com/FDA/FDA+approves+TECVAYLI+and+DARZALEX+FASPRO+combination+for+multiple+myeloma/26122361.html Fri, 06 Mar 2026 08:01:13 -0400 A.06822034 A.19846794 A.27499954 A.30035300 A.50114084 A.50201316 A.50209015 HALO O.00225875 O.00401804 O.00520840 O.00978404 O.01668149 O.07332344 O.20026344 O.20947283 http://www.streetinsider.com/FDA/FDA+approves+TECVAYLI+and+DARZALEX+FASPRO+combination+for+multiple+myeloma/26122361.html <p>The U.S. Food and Drug Administration approved TECVAYLI (teclistamab-cqyv) in combination with DARZALEX FASPRO (daratumumab and hyaluronidase-fihj) for treating adults with relapsed or refractory multiple myeloma who have received at least one prior line of therapy.</p> <p>Johnson & Johnson received the approval based on data from the Phase 3 MajesTEC-3 study. The combination treatment demonstrated an 83% reduction in the risk of disease progression or death compared to standard regimens, with a hazard ratio of 0.17. After a median follow-up of three years, the three-year progression-free survival rate was 83%.</p> <p>Both drugs in the approved combination are administered subcutaneously. DARZALEX FASPRO incorporates http://www.streetinsider.com/FDA/FDA+approves+TECVAYLI+and+DARZALEX+FASPRO+combination+for+multiple+myeloma/26122361.html Fri, 06 Mar 2026 08:01:13 -0400 A.06822034 A.19846794 A.27499954 A.30035300 A.50114084 A.50201316 A.50209015 HALO O.00225875 O.00401804 O.00520840 O.00978404 O.01668149 O.07332344 O.20026344 O.20947283 http://www.streetinsider.com/FDA/FDA+approves+TECVAYLI+and+DARZALEX+FASPRO+combination+for+multiple+myeloma/26122361.html <p>The U.S. Food and Drug Administration approved TECVAYLI (teclistamab-cqyv) in combination with DARZALEX FASPRO (daratumumab and hyaluronidase-fihj) for treating adults with relapsed or refractory multiple myeloma who have received at least one prior line of therapy.</p> <p>Johnson & Johnson received the approval based on data from the Phase 3 MajesTEC-3 study. The combination treatment demonstrated an 83% reduction in the risk of disease progression or death compared to standard regimens, with a hazard ratio of 0.17. After a median follow-up of three years, the three-year progression-free survival rate was 83%.</p> <p>Both drugs in the approved combination are administered subcutaneously. DARZALEX FASPRO incorporates http://www.streetinsider.com/FDA/FDA+approves+TECVAYLI+and+DARZALEX+FASPRO+combination+for+multiple+myeloma/26122361.html Fri, 06 Mar 2026 08:01:13 -0400 A.06822034 A.19846794 A.27499954 A.30035300 A.50114084 A.50201316 A.50209015 HALO O.00225875 O.00401804 O.00520840 O.00978404 O.01668149 O.07332344 O.20026344 O.20947283 http://www.streetinsider.com/FDA/FDA+approves+TECVAYLI+and+DARZALEX+FASPRO+combination+for+multiple+myeloma/26122361.html <p>The U.S. Food and Drug Administration approved TECVAYLI (teclistamab-cqyv) in combination with DARZALEX FASPRO (daratumumab and hyaluronidase-fihj) for treating adults with relapsed or refractory multiple myeloma who have received at least one prior line of therapy.</p> <p>Johnson & Johnson received the approval based on data from the Phase 3 MajesTEC-3 study. The combination treatment demonstrated an 83% reduction in the risk of disease progression or death compared to standard regimens, with a hazard ratio of 0.17. After a median follow-up of three years, the three-year progression-free survival rate was 83%.</p> <p>Both drugs in the approved combination are administered subcutaneously. DARZALEX FASPRO incorporates http://www.streetinsider.com/FDA/FDA+approves+TECVAYLI+and+DARZALEX+FASPRO+combination+for+multiple+myeloma/26122361.html Fri, 06 Mar 2026 08:01:13 -0400 A.06822034 A.19846794 A.27499954 A.30035300 A.50114084 A.50201316 A.50209015 HALO O.00225875 O.00401804 O.00520840 O.00978404 O.01668149 O.07332344 O.20026344 O.20947283 http://www.streetinsider.com/FDA/FDA+approves+TECVAYLI+and+DARZALEX+FASPRO+combination+for+multiple+myeloma/26122361.html <p>The U.S. Food and Drug Administration approved TECVAYLI (teclistamab-cqyv) in combination with DARZALEX FASPRO (daratumumab and hyaluronidase-fihj) for treating adults with relapsed or refractory multiple myeloma who have received at least one prior line of therapy.</p> <p>Johnson & Johnson received the approval based on data from the Phase 3 MajesTEC-3 study. The combination treatment demonstrated an 83% reduction in the risk of disease progression or death compared to standard regimens, with a hazard ratio of 0.17. After a median follow-up of three years, the three-year progression-free survival rate was 83%.</p> <p>Both drugs in the approved combination are administered subcutaneously. DARZALEX FASPRO incorporates http://www.streetinsider.com/FDA/FDA+approves+TECVAYLI+and+DARZALEX+FASPRO+combination+for+multiple+myeloma/26122361.html Fri, 06 Mar 2026 08:01:13 -0400 A.06822034 A.19846794 A.27499954 A.30035300 A.50114084 A.50201316 A.50209015 HALO O.00225875 O.00401804 O.00520840 O.00978404 O.01668149 O.07332344 O.20026344 O.20947283 http://www.streetinsider.com/FDA/FDA+approves+TECVAYLI+and+DARZALEX+FASPRO+combination+for+multiple+myeloma/26122361.html <p>The U.S. Food and Drug Administration approved TECVAYLI (teclistamab-cqyv) in combination with DARZALEX FASPRO (daratumumab and hyaluronidase-fihj) for treating adults with relapsed or refractory multiple myeloma who have received at least one prior line of therapy.</p> <p>Johnson & Johnson received the approval based on data from the Phase 3 MajesTEC-3 study. The combination treatment demonstrated an 83% reduction in the risk of disease progression or death compared to standard regimens, with a hazard ratio of 0.17. After a median follow-up of three years, the three-year progression-free survival rate was 83%.</p> <p>Both drugs in the approved combination are administered subcutaneously. DARZALEX FASPRO incorporates http://www.streetinsider.com/FDA/FDA+approves+TECVAYLI+and+DARZALEX+FASPRO+combination+for+multiple+myeloma/26122361.html Fri, 06 Mar 2026 08:01:13 -0400 A.06822034 A.19846794 A.27499954 A.30035300 A.50114084 A.50201316 A.50209015 HALO O.00225875 O.00401804 O.00520840 O.00978404 O.01668149 O.07332344 O.20026344 O.20947283 http://www.streetinsider.com/FDA/FDA+approves+TECVAYLI+and+DARZALEX+FASPRO+combination+for+multiple+myeloma/26122361.html <p>The U.S. Food and Drug Administration approved TECVAYLI (teclistamab-cqyv) in combination with DARZALEX FASPRO (daratumumab and hyaluronidase-fihj) for treating adults with relapsed or refractory multiple myeloma who have received at least one prior line of therapy.</p> <p>Johnson & Johnson received the approval based on data from the Phase 3 MajesTEC-3 study. The combination treatment demonstrated an 83% reduction in the risk of disease progression or death compared to standard regimens, with a hazard ratio of 0.17. After a median follow-up of three years, the three-year progression-free survival rate was 83%.</p> <p>Both drugs in the approved combination are administered subcutaneously. DARZALEX FASPRO incorporates http://www.streetinsider.com/FDA/FDA+approves+TECVAYLI+and+DARZALEX+FASPRO+combination+for+multiple+myeloma/26122361.html Fri, 06 Mar 2026 08:01:13 -0400 A.06822034 A.19846794 A.27499954 A.30035300 A.50114084 A.50201316 A.50209015 HALO O.00225875 O.00401804 O.00520840 O.00978404 O.01668149 O.07332344 O.20026344 O.20947283 http://www.streetinsider.com/FDA/FDA+approves+TECVAYLI+and+DARZALEX+FASPRO+combination+for+multiple+myeloma/26122361.html <p>The U.S. Food and Drug Administration approved TECVAYLI (teclistamab-cqyv) in combination with DARZALEX FASPRO (daratumumab and hyaluronidase-fihj) for treating adults with relapsed or refractory multiple myeloma who have received at least one prior line of therapy.</p> <p>Johnson & Johnson received the approval based on data from the Phase 3 MajesTEC-3 study. The combination treatment demonstrated an 83% reduction in the risk of disease progression or death compared to standard regimens, with a hazard ratio of 0.17. After a median follow-up of three years, the three-year progression-free survival rate was 83%.</p> <p>Both drugs in the approved combination are administered subcutaneously. DARZALEX FASPRO incorporates http://www.streetinsider.com/FDA/FDA+approves+TECVAYLI+and+DARZALEX+FASPRO+combination+for+multiple+myeloma/26122361.html Fri, 06 Mar 2026 08:01:13 -0400 A.06822034 A.19846794 A.27499954 A.30035300 A.50114084 A.50201316 A.50209015 HALO O.00225875 O.00401804 O.00520840 O.00978404 O.01668149 O.07332344 O.20026344 O.20947283 http://www.streetinsider.com/FDA/FDA+approves+TECVAYLI+and+DARZALEX+FASPRO+combination+for+multiple+myeloma/26122361.html <p>The U.S. Food and Drug Administration approved TECVAYLI (teclistamab-cqyv) in combination with DARZALEX FASPRO (daratumumab and hyaluronidase-fihj) for treating adults with relapsed or refractory multiple myeloma who have received at least one prior line of therapy.</p> <p>Johnson & Johnson received the approval based on data from the Phase 3 MajesTEC-3 study. The combination treatment demonstrated an 83% reduction in the risk of disease progression or death compared to standard regimens, with a hazard ratio of 0.17. After a median follow-up of three years, the three-year progression-free survival rate was 83%.</p> <p>Both drugs in the approved combination are administered subcutaneously. DARZALEX FASPRO incorporates http://www.streetinsider.com/FDA/FDA+approves+TECVAYLI+and+DARZALEX+FASPRO+combination+for+multiple+myeloma/26122361.html Fri, 06 Mar 2026 08:01:13 -0400 A.06822034 A.19846794 A.27499954 A.30035300 A.50114084 A.50201316 A.50209015 HALO O.00225875 O.00401804 O.00520840 O.00978404 O.01668149 O.07332344 O.20026344 O.20947283 http://www.streetinsider.com/FDA/FDA+approves+TECVAYLI+and+DARZALEX+FASPRO+combination+for+multiple+myeloma/26122361.html <p>The U.S. Food and Drug Administration approved TECVAYLI (teclistamab-cqyv) in combination with DARZALEX FASPRO (daratumumab and hyaluronidase-fihj) for treating adults with relapsed or refractory multiple myeloma who have received at least one prior line of therapy.</p> <p>Johnson & Johnson received the approval based on data from the Phase 3 MajesTEC-3 study. The combination treatment demonstrated an 83% reduction in the risk of disease progression or death compared to standard regimens, with a hazard ratio of 0.17. After a median follow-up of three years, the three-year progression-free survival rate was 83%.</p> <p>Both drugs in the approved combination are administered subcutaneously. DARZALEX FASPRO incorporates http://www.streetinsider.com/FDA/FDA+approves+TECVAYLI+and+DARZALEX+FASPRO+combination+for+multiple+myeloma/26122361.html Fri, 06 Mar 2026 08:01:13 -0400 A.06822034 A.19846794 A.27499954 A.30035300 A.50114084 A.50201316 A.50209015 HALO O.00225875 O.00401804 O.00520840 O.00978404 O.01668149 O.07332344 O.20026344 O.20947283 http://www.streetinsider.com/FDA/FDA+approves+TECVAYLI+and+DARZALEX+FASPRO+combination+for+multiple+myeloma/26122361.html <p>The U.S. Food and Drug Administration approved TECVAYLI (teclistamab-cqyv) in combination with DARZALEX FASPRO (daratumumab and hyaluronidase-fihj) for treating adults with relapsed or refractory multiple myeloma who have received at least one prior line of therapy.</p> <p>Johnson & Johnson received the approval based on data from the Phase 3 MajesTEC-3 study. The combination treatment demonstrated an 83% reduction in the risk of disease progression or death compared to standard regimens, with a hazard ratio of 0.17. After a median follow-up of three years, the three-year progression-free survival rate was 83%.</p> <p>Both drugs in the approved combination are administered subcutaneously. DARZALEX FASPRO incorporates http://www.streetinsider.com/FDA/FDA+approves+TECVAYLI+and+DARZALEX+FASPRO+combination+for+multiple+myeloma/26122361.html Fri, 06 Mar 2026 08:01:13 -0400 A.06822034 A.19846794 A.27499954 A.30035300 A.50114084 A.50201316 A.50209015 HALO O.00225875 O.00401804 O.00520840 O.00978404 O.01668149 O.07332344 O.20026344 O.20947283 http://www.streetinsider.com/FDA/FDA+approves+TECVAYLI+and+DARZALEX+FASPRO+combination+for+multiple+myeloma/26122361.html <p>The U.S. Food and Drug Administration approved TECVAYLI (teclistamab-cqyv) in combination with DARZALEX FASPRO (daratumumab and hyaluronidase-fihj) for treating adults with relapsed or refractory multiple myeloma who have received at least one prior line of therapy.</p> <p>Johnson & Johnson received the approval based on data from the Phase 3 MajesTEC-3 study. The combination treatment demonstrated an 83% reduction in the risk of disease progression or death compared to standard regimens, with a hazard ratio of 0.17. After a median follow-up of three years, the three-year progression-free survival rate was 83%.</p> <p>Both drugs in the approved combination are administered subcutaneously. DARZALEX FASPRO incorporates http://www.streetinsider.com/FDA/FDA+approves+TECVAYLI+and+DARZALEX+FASPRO+combination+for+multiple+myeloma/26122361.html Fri, 06 Mar 2026 08:01:13 -0400 A.06822034 A.19846794 A.27499954 A.30035300 A.50114084 A.50201316 A.50209015 HALO O.00225875 O.00401804 O.00520840 O.00978404 O.01668149 O.07332344 O.20026344 O.20947283 http://www.streetinsider.com/FDA/FDA+approves+TECVAYLI+and+DARZALEX+FASPRO+combination+for+multiple+myeloma/26122361.html <p>The U.S. Food and Drug Administration approved TECVAYLI (teclistamab-cqyv) in combination with DARZALEX FASPRO (daratumumab and hyaluronidase-fihj) for treating adults with relapsed or refractory multiple myeloma who have received at least one prior line of therapy.</p> <p>Johnson & Johnson received the approval based on data from the Phase 3 MajesTEC-3 study. The combination treatment demonstrated an 83% reduction in the risk of disease progression or death compared to standard regimens, with a hazard ratio of 0.17. After a median follow-up of three years, the three-year progression-free survival rate was 83%.</p> <p>Both drugs in the approved combination are administered subcutaneously. DARZALEX FASPRO incorporates http://www.streetinsider.com/FDA/FDA+approves+TECVAYLI+and+DARZALEX+FASPRO+combination+for+multiple+myeloma/26122361.html Fri, 06 Mar 2026 08:01:13 -0400 A.06822034 A.19846794 A.27499954 A.30035300 A.50114084 A.50201316 A.50209015 HALO O.00225875 O.00401804 O.00520840 O.00978404 O.01668149 O.07332344 O.20026344 O.20947283 http://www.streetinsider.com/Press+Releases/U.S.+FDA+Approves+TECVAYLI%C2%AE+in+Combination+with+DARZALEX+FASPRO%C2%AE+for+RelapsedRefractory+Multiple+Myeloma/26122323.html <div class="xn-content"> <p class="prntac"><i>FDA approval based on Phase 3 data demonstrating statistically significant improvements in progression</i><i>‑free survival and overall survival versus standard of care regimens</i></p><p><span class="legendSpanClass"><location value="LU/us.ca.sandgo" idsrc="xmltag.org" >SAN DIEGO</location></span>, <span class="legendSpanClass"><chron>March 6, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:HALO" idsrc="xmltag.org" >Halozyme Therapeutics, Inc.</span> (NASDAQ: HALO) (<span value="ACORN:3003530008" idsrc="xmltag.org" >Halozyme</span>) today announced that Johnson &amp; Johnson has received approval from the <span value="ACORN:0682203466" idsrc="xmltag.org" >U.S. Food and Drug Administration</span> (FDA) for TECVAYLI<i>®</i> (teclistamab-cqyv) in combination with DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) for the treatment of adults with relapsed or refractory multiple myeloma (RRMM) who have received at least one prior line of therapy.¹</p><p>"The http://www.streetinsider.com/Press+Releases/U.S.+FDA+Approves+TECVAYLI%C2%AE+in+Combination+with+DARZALEX+FASPRO%C2%AE+for+RelapsedRefractory+Multiple+Myeloma/26122323.html Fri, 06 Mar 2026 08:00:00 -0400 A.06822034 A.19846794 A.27499954 A.30035300 A.50114084 A.50201316 A.50209015 HALO O.00225875 O.00401804 O.00520840 O.00978404 O.01668149 O.07332344 O.20026344 O.20947283 http://www.streetinsider.com/Press+Releases/U.S.+FDA+Approves+TECVAYLI%C2%AE+in+Combination+with+DARZALEX+FASPRO%C2%AE+for+RelapsedRefractory+Multiple+Myeloma/26122323.html <div class="xn-content"> <p class="prntac"><i>FDA approval based on Phase 3 data demonstrating statistically significant improvements in progression</i><i>‑free survival and overall survival versus standard of care regimens</i></p><p><span class="legendSpanClass"><location value="LU/us.ca.sandgo" idsrc="xmltag.org" >SAN DIEGO</location></span>, <span class="legendSpanClass"><chron>March 6, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:HALO" idsrc="xmltag.org" >Halozyme Therapeutics, Inc.</span> (NASDAQ: HALO) (<span value="ACORN:3003530008" idsrc="xmltag.org" >Halozyme</span>) today announced that Johnson &amp; Johnson has received approval from the <span value="ACORN:0682203466" idsrc="xmltag.org" >U.S. Food and Drug Administration</span> (FDA) for TECVAYLI<i>®</i> (teclistamab-cqyv) in combination with DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) for the treatment of adults with relapsed or refractory multiple myeloma (RRMM) who have received at least one prior line of therapy.¹</p><p>"The http://www.streetinsider.com/Press+Releases/U.S.+FDA+Approves+TECVAYLI%C2%AE+in+Combination+with+DARZALEX+FASPRO%C2%AE+for+RelapsedRefractory+Multiple+Myeloma/26122323.html Fri, 06 Mar 2026 08:00:00 -0400 A.06822034 A.19846794 A.27499954 A.30035300 A.50114084 A.50201316 A.50209015 HALO O.00225875 O.00401804 O.00520840 O.00978404 O.01668149 O.07332344 O.20026344 O.20947283 http://www.streetinsider.com/Press+Releases/U.S.+FDA+Approves+TECVAYLI%C2%AE+in+Combination+with+DARZALEX+FASPRO%C2%AE+for+RelapsedRefractory+Multiple+Myeloma/26122323.html <div class="xn-content"> <p class="prntac"><i>FDA approval based on Phase 3 data demonstrating statistically significant improvements in progression</i><i>‑free survival and overall survival versus standard of care regimens</i></p><p><span class="legendSpanClass"><location value="LU/us.ca.sandgo" idsrc="xmltag.org" >SAN DIEGO</location></span>, <span class="legendSpanClass"><chron>March 6, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:HALO" idsrc="xmltag.org" >Halozyme Therapeutics, Inc.</span> (NASDAQ: HALO) (<span value="ACORN:3003530008" idsrc="xmltag.org" >Halozyme</span>) today announced that Johnson &amp; Johnson has received approval from the <span value="ACORN:0682203466" idsrc="xmltag.org" >U.S. Food and Drug Administration</span> (FDA) for TECVAYLI<i>®</i> (teclistamab-cqyv) in combination with DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) for the treatment of adults with relapsed or refractory multiple myeloma (RRMM) who have received at least one prior line of therapy.¹</p><p>"The http://www.streetinsider.com/Press+Releases/U.S.+FDA+Approves+TECVAYLI%C2%AE+in+Combination+with+DARZALEX+FASPRO%C2%AE+for+RelapsedRefractory+Multiple+Myeloma/26122323.html Fri, 06 Mar 2026 08:00:00 -0400 A.06822034 A.19846794 A.27499954 A.30035300 A.50114084 A.50201316 A.50209015 HALO O.00225875 O.00401804 O.00520840 O.00978404 O.01668149 O.07332344 O.20026344 O.20947283 http://www.streetinsider.com/Press+Releases/U.S.+FDA+Approves+TECVAYLI%C2%AE+in+Combination+with+DARZALEX+FASPRO%C2%AE+for+RelapsedRefractory+Multiple+Myeloma/26122323.html <div class="xn-content"> <p class="prntac"><i>FDA approval based on Phase 3 data demonstrating statistically significant improvements in progression</i><i>‑free survival and overall survival versus standard of care regimens</i></p><p><span class="legendSpanClass"><location value="LU/us.ca.sandgo" idsrc="xmltag.org" >SAN DIEGO</location></span>, <span class="legendSpanClass"><chron>March 6, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:HALO" idsrc="xmltag.org" >Halozyme Therapeutics, Inc.</span> (NASDAQ: HALO) (<span value="ACORN:3003530008" idsrc="xmltag.org" >Halozyme</span>) today announced that Johnson &amp; Johnson has received approval from the <span value="ACORN:0682203466" idsrc="xmltag.org" >U.S. Food and Drug Administration</span> (FDA) for TECVAYLI<i>®</i> (teclistamab-cqyv) in combination with DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) for the treatment of adults with relapsed or refractory multiple myeloma (RRMM) who have received at least one prior line of therapy.¹</p><p>"The http://www.streetinsider.com/Press+Releases/U.S.+FDA+Approves+TECVAYLI%C2%AE+in+Combination+with+DARZALEX+FASPRO%C2%AE+for+RelapsedRefractory+Multiple+Myeloma/26122323.html Fri, 06 Mar 2026 08:00:00 -0400 A.06822034 A.19846794 A.27499954 A.30035300 A.50114084 A.50201316 A.50209015 HALO O.00225875 O.00401804 O.00520840 O.00978404 O.01668149 O.07332344 O.20026344 O.20947283 http://www.streetinsider.com/Press+Releases/U.S.+FDA+Approves+TECVAYLI%C2%AE+in+Combination+with+DARZALEX+FASPRO%C2%AE+for+RelapsedRefractory+Multiple+Myeloma/26122323.html <div class="xn-content"> <p class="prntac"><i>FDA approval based on Phase 3 data demonstrating statistically significant improvements in progression</i><i>‑free survival and overall survival versus standard of care regimens</i></p><p><span class="legendSpanClass"><location value="LU/us.ca.sandgo" idsrc="xmltag.org" >SAN DIEGO</location></span>, <span class="legendSpanClass"><chron>March 6, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:HALO" idsrc="xmltag.org" >Halozyme Therapeutics, Inc.</span> (NASDAQ: HALO) (<span value="ACORN:3003530008" idsrc="xmltag.org" >Halozyme</span>) today announced that Johnson &amp; Johnson has received approval from the <span value="ACORN:0682203466" idsrc="xmltag.org" >U.S. Food and Drug Administration</span> (FDA) for TECVAYLI<i>®</i> (teclistamab-cqyv) in combination with DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) for the treatment of adults with relapsed or refractory multiple myeloma (RRMM) who have received at least one prior line of therapy.¹</p><p>"The http://www.streetinsider.com/Press+Releases/U.S.+FDA+Approves+TECVAYLI%C2%AE+in+Combination+with+DARZALEX+FASPRO%C2%AE+for+RelapsedRefractory+Multiple+Myeloma/26122323.html Fri, 06 Mar 2026 08:00:00 -0400 A.06822034 A.19846794 A.27499954 A.30035300 A.50114084 A.50201316 A.50209015 HALO O.00225875 O.00401804 O.00520840 O.00978404 O.01668149 O.07332344 O.20026344 O.20947283 http://www.streetinsider.com/Press+Releases/U.S.+FDA+Approves+TECVAYLI%C2%AE+in+Combination+with+DARZALEX+FASPRO%C2%AE+for+RelapsedRefractory+Multiple+Myeloma/26122323.html <div class="xn-content"> <p class="prntac"><i>FDA approval based on Phase 3 data demonstrating statistically significant improvements in progression</i><i>‑free survival and overall survival versus standard of care regimens</i></p><p><span class="legendSpanClass"><location value="LU/us.ca.sandgo" idsrc="xmltag.org" >SAN DIEGO</location></span>, <span class="legendSpanClass"><chron>March 6, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:HALO" idsrc="xmltag.org" >Halozyme Therapeutics, Inc.</span> (NASDAQ: HALO) (<span value="ACORN:3003530008" idsrc="xmltag.org" >Halozyme</span>) today announced that Johnson &amp; Johnson has received approval from the <span value="ACORN:0682203466" idsrc="xmltag.org" >U.S. Food and Drug Administration</span> (FDA) for TECVAYLI<i>®</i> (teclistamab-cqyv) in combination with DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) for the treatment of adults with relapsed or refractory multiple myeloma (RRMM) who have received at least one prior line of therapy.¹</p><p>"The http://www.streetinsider.com/Press+Releases/U.S.+FDA+Approves+TECVAYLI%C2%AE+in+Combination+with+DARZALEX+FASPRO%C2%AE+for+RelapsedRefractory+Multiple+Myeloma/26122323.html Fri, 06 Mar 2026 08:00:00 -0400 A.06822034 A.19846794 A.27499954 A.30035300 A.50114084 A.50201316 A.50209015 HALO O.00225875 O.00401804 O.00520840 O.00978404 O.01668149 O.07332344 O.20026344 O.20947283 http://www.streetinsider.com/Press+Releases/U.S.+FDA+Approves+TECVAYLI%C2%AE+in+Combination+with+DARZALEX+FASPRO%C2%AE+for+RelapsedRefractory+Multiple+Myeloma/26122323.html <div class="xn-content"> <p class="prntac"><i>FDA approval based on Phase 3 data demonstrating statistically significant improvements in progression</i><i>‑free survival and overall survival versus standard of care regimens</i></p><p><span class="legendSpanClass"><location value="LU/us.ca.sandgo" idsrc="xmltag.org" >SAN DIEGO</location></span>, <span class="legendSpanClass"><chron>March 6, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:HALO" idsrc="xmltag.org" >Halozyme Therapeutics, Inc.</span> (NASDAQ: HALO) (<span value="ACORN:3003530008" idsrc="xmltag.org" >Halozyme</span>) today announced that Johnson &amp; Johnson has received approval from the <span value="ACORN:0682203466" idsrc="xmltag.org" >U.S. Food and Drug Administration</span> (FDA) for TECVAYLI<i>®</i> (teclistamab-cqyv) in combination with DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) for the treatment of adults with relapsed or refractory multiple myeloma (RRMM) who have received at least one prior line of therapy.¹</p><p>"The http://www.streetinsider.com/Press+Releases/U.S.+FDA+Approves+TECVAYLI%C2%AE+in+Combination+with+DARZALEX+FASPRO%C2%AE+for+RelapsedRefractory+Multiple+Myeloma/26122323.html Fri, 06 Mar 2026 08:00:00 -0400 A.06822034 A.19846794 A.27499954 A.30035300 A.50114084 A.50201316 A.50209015 HALO O.00225875 O.00401804 O.00520840 O.00978404 O.01668149 O.07332344 O.20026344 O.20947283